{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:57:04Z","timestamp":1790834224809,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"This study was funded by Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12872-017-0674-3","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T22:19:39Z","timestamp":1504649979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-4983","authenticated-orcid":false,"given":"Carmine Dario","family":"Vizza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Jansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Teal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,6]]},"reference":[{"key":"674_CR1","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","volume":"34","author":"T Lung","year":"2009","unstructured":"Task Force for D, Treatment of Pulmonary Hypertension of European Society of C, European Respiratory S, International Society of H, Lung T, Galie N, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219\u201363.","journal-title":"Eur Respir J"},{"key":"674_CR2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425\u201336.","journal-title":"N Engl J Med"},{"key":"674_CR3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330\u201340.","journal-title":"N Engl J Med"},{"key":"674_CR4","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","volume":"62","author":"N Galie","year":"2013","unstructured":"Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D60\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"674_CR5","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"VV McLaughlin","year":"2009","unstructured":"McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573\u2013619.","journal-title":"J Am Coll Cardiol"},{"key":"674_CR6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/1753465811411602","volume":"5","author":"AT Levinson","year":"2011","unstructured":"Levinson AT, Klinger JR. Combination therapy for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis. 2011;5:419\u201330.","journal-title":"Ther Adv Respir Dis"},{"key":"674_CR7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.amjcard.2011.06.021","volume":"108","author":"BD Fox","year":"2011","unstructured":"Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol. 2011;108:1177\u201382.","journal-title":"Am J Cardiol"},{"key":"674_CR8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000334431","volume":"120","author":"Y Bai","year":"2011","unstructured":"Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology. 2011;120:157\u201365.","journal-title":"Cardiology"},{"key":"674_CR9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0091270009341182","volume":"49","author":"E Gruenig","year":"2009","unstructured":"Gruenig E, Michelakis E, Vachiery JL, Vizza CD, Meyer FJ, Doelberg M, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol. 2009;49:1343\u201352.","journal-title":"J Clin Pharmacol"},{"key":"674_CR10","doi-asserted-by":"crossref","first-page":"840A","DOI":"10.1378\/chest.10295","volume":"138","author":"R Benza","year":"2010","unstructured":"Benza R, Gupta H, Soto F, Park M, Torres F, Frey N, et al. Safety and efficacy of bosentan in combination with sildenafil in PAH patients who experience inadequate clinical response to monotherapy: the COMPASS-3 study [abstract]. Chest. 2010;138:840A.","journal-title":"Chest"},{"key":"674_CR11","volume-title":"Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study [abstract]","author":"F Torres","year":"2011","unstructured":"Torres F, Gupta H, Soto F, Park M, Frey N, Murali S, et al. Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study [abstract]. Amsterdam, Netherlands: European Respiratory Society International Congress: September 25; 2011. Available at: \nhttp:\/\/www.ers-education.org\/events\/international-congress\/amsterdam-2011.aspx?idParent=106250"},{"key":"674_CR12","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Galie","year":"2005","unstructured":"Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148\u201357.","journal-title":"N Engl J Med"},{"key":"674_CR13","unstructured":"US Food and Drug Administration. In: Pfizer Inc. 2005."},{"key":"674_CR14","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1016\/j.jacc.2004.02.032","volume":"43","author":"RJ Barst","year":"2004","unstructured":"Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:40S\u20137S.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"674_CR15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5271\/sjweh.1815","volume":"16","author":"G Borg","year":"1990","unstructured":"Borg G. Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health. 1990;16(Suppl 1):55\u20138.","journal-title":"Scand J Work Environ Health"},{"key":"674_CR16","first-page":"377","volume":"14","author":"GA Borg","year":"1982","unstructured":"Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377\u201381.","journal-title":"Med Sci Sports Exerc"},{"key":"674_CR17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","volume":"30","author":"RJ Barst","year":"2011","unstructured":"Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transpl. 2011;30:632\u201343.","journal-title":"J Heart Lung Transpl."},{"key":"674_CR18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896\u2013903.","journal-title":"N Engl J Med"},{"key":"674_CR19","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","volume":"35","author":"A Treiber","year":"2007","unstructured":"Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin a, rifampicin, and sildenafil. Drug Metab Dispos Biol Fate Chem. 2007;35:1400\u20137.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"674_CR20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-007-0408-z","volume":"64","author":"G Burgess","year":"2008","unstructured":"Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008;64:43\u201350.","journal-title":"Eur J Clin Pharmacol"},{"key":"674_CR21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","volume":"60","author":"GA Paul","year":"2005","unstructured":"Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005;60:107\u201312.","journal-title":"Br J Clin Pharmacol"},{"key":"674_CR22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/hr.2014.28","volume":"37","author":"Y Zhuang","year":"2014","unstructured":"Zhuang Y, Jiang B, Gao H, Zhao W. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res Official J Japanese Soc Hypertens. 2014;37:507\u201312.","journal-title":"Hypertens Res Official J Japanese Soc Hypertens"},{"key":"674_CR23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Galie","year":"2015","unstructured":"Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834\u201344.","journal-title":"N Engl J Med"},{"key":"674_CR24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","volume":"46","author":"V McLaughlin","year":"2015","unstructured":"McLaughlin V, Channick RN, Ghofrani HA, Lemarie JC, Naeije R, Packer M, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46:405\u201313.","journal-title":"Eur Respir J"},{"key":"674_CR25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/CIRCULATIONAHA.112.118547","volume":"126","author":"HW Farber","year":"2012","unstructured":"Farber HW. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square peg into a round hole? Circulation. 2012;126:258\u201360.","journal-title":"Circulation"},{"key":"674_CR26","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2012.01.083","volume":"60","author":"G Savarese","year":"2012","unstructured":"Savarese G, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60:1192\u2013201.","journal-title":"J Am Coll Cardiol"},{"key":"674_CR27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.201206-1137ED","volume":"186","author":"LJ Rubin","year":"2012","unstructured":"Rubin LJ. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? Am J Respir Crit Care Med. 2012;186:396\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"674_CR28","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"N Galie","year":"2009","unstructured":"Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493\u2013537.","journal-title":"Eur Heart J"},{"key":"674_CR29","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.04.00051104","volume":"24","author":"MM Hoeper","year":"2004","unstructured":"Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004;24:1007\u201310.","journal-title":"Eur Respir J"},{"key":"674_CR30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2362.2006.01692.x","volume":"36","author":"K Lunze","year":"2006","unstructured":"Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Investig. 2006;36:32\u20138.","journal-title":"Eur J Clin Investig"},{"key":"674_CR31","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1136\/hrt.2005.085118","volume":"92","author":"SA Wolferen van","year":"2006","unstructured":"van Wolferen SA, Boonstra A, Marcus JT, Marques KM, Bronzwaer JG, Postmus PE, et al. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. Heart. 2006;92:1860\u20131.","journal-title":"Heart"},{"key":"674_CR32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1183\/09031936.00081706","volume":"29","author":"SC Mathai","year":"2007","unstructured":"Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007;29:469\u201375.","journal-title":"Eur Respir J"},{"key":"674_CR33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1155\/2008\/897102","volume":"15","author":"NR Porhownik","year":"2008","unstructured":"Porhownik NR, Al-Sharif H, Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J. 2008;15:427\u201330.","journal-title":"Can Respir J"},{"key":"674_CR34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijcard.2010.10.051","volume":"155","author":"M D'Alto","year":"2012","unstructured":"D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155:378\u201382.","journal-title":"Int J Cardiol"},{"key":"674_CR35","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","volume":"31","author":"K Iversen","year":"2010","unstructured":"Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31:1124\u201331.","journal-title":"Eur Heart J"},{"key":"674_CR36","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","volume":"371","author":"N Galie","year":"2008","unstructured":"Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093\u2013100.","journal-title":"Lancet"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-017-0674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T22:20:02Z","timestamp":1504650002000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-017-0674-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,6]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1186\/s12872-017-0674-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,6]]},"article-number":"239"}}